Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Transcriptional stratification reveals distinct molecular subtypes with treatment-specific outcomes in multiple myeloma patients from the GEM2017FIT trial

Blood (2025) 146 (Supplement 1): 496.

https://doi.org/10.1182/blood-2025-496

Published: 2025

Journal Articles

Combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients (Pts) with multiple myeloma (MM)

Blood (2025) 146 (Supplement 1): 494.

https://doi.org/10.1182/blood-2025-494

Published: 2025

Journal Articles

Head-to-head longitudinal comparison of two mass spectrometry-based methods for monitoring monoclonal proteins in multiple myeloma: Analytical and clinical insights from the GEM-CESAR trial

Blood (2025) 146 (Supplement 1): 2238.

https://doi.org/10.1182/blood-2025-2238

Published: 2025

Journal Articles

Outcomes of patients with light-chain amyloidosis after heart transplantation: A single center cohort.

Jose Miguel Mateos Perez, Carlos Fernandez de Larrea, José Tomás Ortiz, Luis Fernando Quintana, Joaquim Casals, Adriana Patricia Garcia, Natalia Tovar, Luis Gerardo Rodríguez-Lobato, David Moreno, Aina Oliver-Caldes, Alberto Lazaro García, Marta Farrero, Joan Batista Blade Creixenti, Laura Rosiñol Dachs, Maria Teresa Cibeira López

Blood (2025) 146 (Supplement 1): 7494.

https://doi.org/10.1182/blood-2025-7494

Published: 2025

Journal Articles

Comprehensive DNA/RNA-based targeted sequencing for molecular karyotyping and clonality assessment in newly diagnosed multiple myeloma patients

Blood (2025) 146 (Supplement 1): 2562.

https://doi.org/10.1182/blood-2025-2562

Published: 2025

Journal Articles

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

Blood (2025) 146 (Supplement 1): 922.

https://doi.org/10.1182/blood-2025-922

Published: 2025

Journal Articles

Minimally invasive assessment of peripheral residual disease (PRD) during maintenance or observation in patients (Pts) with multiple myeloma (MM): An update from the GEM2017FIT clinical trial

Blood (2025) 146 (Supplement 1): 919.

https://doi.org/10.1182/blood-2025-919

Published: 2025

Journal Articles

Operational cure in patients with newly diagnosed multiple myeloma after autologous stem cell transplantation: Long-term survivors and impact of induction regimens.

Jose Miguel Mateos Perez, Francesc Fernández-Avilés, Maria Teresa Cibeira López, Maria Carmen Martinez Munoz, Carlos Fernandez de Larrea, Natalia Tovar, Luis Gerardo Rodríguez-Lobato, Maria Suarez-Lledo, Maria Queralt Salas Gay, David Moreno, Aina Oliver-Caldes, Alberto Lazaro García, Montserrat Rovira, Joan Batista Blade Creixenti, Laura Rosiñol Dachs

Blood (2025) 146 (Supplement 1): 5776.

https://doi.org/10.1182/blood-2025-5776

Published: 2025

Journal Articles

Ending the undetermined significance of monoclonal gammopathies (MGUS): First results of the nomoremgus study

Marta Lasa, Esperanza Martin-Sanchez, Aintzane Zabaleta, Diego Alignani, Carmen Gonzalez, Noemi Puig, Elena Alejo, Jorge Labrador, Maria Casanova Espinosa, Laura Rosiñol Dachs, Sebastián Garzón, Enrique Ocio, Albert Pérez-Montaña, Irene Romera, Carmen Couto, Sunil Lakhwani, Felipe Prosper, Adrian Alegre, Elena Cabezudo, Itziar Carro, Cristina Motlló, Montserrat Cortes, Isabel Maria Garcia Cabrera, Marta Romera, Javier de la Rubia, Andrea Manubens, Alexia Suarez Cabrera, Fernando Escalante Barrigón, Carlos Aguilar-Franco, Raquel Del Campo, Maria Esther Clavero Sanchez, Joaquin Martinez-Lopez, Valentin Cabanas Perianes, María-Jesús Blanchard, Ana Lopez-Guia, Diana Sanchez Arguello, Albert Oriol, Marta Reinoso -Segura, María Lourdes Amador Barciela, Celina Benavente Cuesta, Jose Maria Arguiñano PEREZ, Beatriz Ordoñez, Francisco Taboada, Joan Batista Blade Creixenti, María-Victoria Mateos, Juan-Jose Lahuerta Palacios, Jesus San-Miguel, Bruno Paiva

Blood (2025) 146 (Supplement 1): 578.

https://doi.org/10.1182/blood-2025-578

Published: 2025

Journal Articles

Integrative omics analysis of TP53 in multiple myeloma patients

Cristina De Ramón Sánchez, Elizabeta A Rojas, Irena Misieweicz, Maria García-Alvarez, Myriam Cuadrado, Sara Cristobal, Ignacio J Cardona-Benavides, Isabel M Isidro, Maria Calasanz, Miguel Alcoceba, Ramon Garcia-Sanz, Laura Rosiñol Dachs, Joaquin Martinez-Lopez, Joan Batista Blade Creixenti, Juan-Jose Lahuerta Palacios, Jesus San-Miguel, María-Victoria Mateos, Luis Antonio Corchete Sanchez, Norma Gutiérrez

Blood (2025) 146 (Supplement 1): 2162.

https://doi.org/10.1182/blood-2025-2162

Published: 2025

Journal Articles

Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd

Blood (2025) 146 (Supplement 1): 371.

https://doi.org/10.1182/blood-2025-371

Published: 2025

Journal Articles

Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features

Blood (2025) 146 (Supplement 1): 366.

https://doi.org/10.1182/blood-2025-366

Published: 2025

Journal Articles

Immune biomarkers of increased risk of infection in multiple myeloma (MM)

Aintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V. Kostopoulos, Romanos Sklavenitis-Pistofidis, Febe Smits, Carmen Roncal, Michelle Aranha, David Zihala, Michaela Machu, Nikolaos Tsakirakis, Panagiotis Bakouros, Ourania Tsitsilonis, Eirini Solia, Cristina Moreno, Catarina Maia, Esperanza Martin-Sanchez, José J. Perez, Cristina Encinas, Rafael Rios Tamayo, Albert Oriol, María-Jesús Blanchard, Felipe de Arriba, Esther González García, Sunil Lakhwani, Anna Sureda Balarí, Valentin Cabanas Perianes, Fernando Escalante Barrigón, Estrella Carrillo-Cruz, Albert Pérez-Montaña, Enrique Ocio, Joan Bargay, Alberto Orfao, Tomas Jelinek, Irene Ghobrial, Tuna Mutis, Sonja Zweegman, Evangelos Terpos, Efstathios Kastritis, Joaquin Martinez-Lopez, Juan-Jose Lahuerta Palacios, Carlos Fernandez de Larrea, Laura Rosiñol, Joan Batista Blade Creixenti, Paula Rodriguez-Otero, María-Victoria Mateos, Jesus San-Miguel, Maria Teresa Cedena Romero, Noemí Puig, Bruno Paiva

Blood (2025) 146 (Supplement 1): 365.

https://doi.org/10.1182/blood-2025-365

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Transcriptional stratification reveals distinct molecular subtypes with treatment-specific outcomes in multiple myeloma patients from the GEM2017FIT trial

Combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients (Pts) with multiple myeloma (MM)

Head-to-head longitudinal comparison of two mass spectrometry-based methods for monitoring monoclonal proteins in multiple myeloma: Analytical and clinical insights from the GEM-CESAR trial

Outcomes of patients with light-chain amyloidosis after heart transplantation: A single center cohort.

Comprehensive DNA/RNA-based targeted sequencing for molecular karyotyping and clonality assessment in newly diagnosed multiple myeloma patients

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

Minimally invasive assessment of peripheral residual disease (PRD) during maintenance or observation in patients (Pts) with multiple myeloma (MM): An update from the GEM2017FIT clinical trial

Operational cure in patients with newly diagnosed multiple myeloma after autologous stem cell transplantation: Long-term survivors and impact of induction regimens.

Ending the undetermined significance of monoclonal gammopathies (MGUS): First results of the nomoremgus study

Integrative omics analysis of TP53 in multiple myeloma patients

Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd

Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features

Immune biomarkers of increased risk of infection in multiple myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only